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Background: Midaortic syndrome (MAS) is associated with severe hypertension, which can be refractory to medical management and associated 
with significant morbidity and mortality.
methods: We describe our 30-year experience with multidisciplinary management of patients with MAS.
results: Fifty-three patients were included with a median age at presentation of 6.7 (birth - 28.7) years. All patients underwent medical 
management and 35 patients (66%) underwent invasive management (percutaneous techniques: 21; surgical techniques: 5; both: 9). At most recent 
follow-up, the majority of the patients (67%) were normotensive. The median duration between the time of presentation and achievement of blood 
pressure control was 5.7 (0.4 - 21.1) years. The median number of anti-hypertensive medications was 1 (0 - 5). Percutaneous interventions were 
acutely successful in decreasing the gradient across the obstruction and % luminal stenosis. However, freedom from reintervention was only 58% at 
1 year and 33% at 5 years. Freedom from reintervention after a surgical procedure was longer: 83% at 1 year and 72% at 10 years.
conclusions: a multidisciplinary management strategy, which couples comprehensive medical management with catheter-based and surgical 
interventions, can lead to adequate blood pressure control and preservation of end-organ function in the majority of patients with MAS.
